ClinicalTrials.Veeva

Menu

Minimal HePatic Encephalopathy Among CiRrhotics. A Cross SEctional, Clinico-EpidEmiological, Multi-Centre, Study in Patients of PakisTan (Preempt)

Abbott logo

Abbott

Status

Completed

Conditions

Hepatic Encephalopathy

Study type

Observational

Funder types

Industry

Identifiers

NCT02613858
EPIDI038

Details and patient eligibility

About

The Preempt study is likely to help determine the frequency of patients suffering from Minimal Hepatic Encephalopathy (MHE) and are cirrhotics. It will also enable us to know about the Quality of life of these patients.

Enrollment

550 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients of either sex, 18-65 years of age, who have attended school at least till the 5th Class/Standard having an established diagnosis of liver cirrhosis without any overt symptoms at time of testing with Grade 0 of West Haven criteria.
  • Patients willing to undergo the neuropsychological (NP) tests and to complete the SF-36 questionnaire for the estimation of Health Related Quality of Life (HRQOL).
  • Patients willing to provide written authorization to provide data for the study.

Exclusion criteria

  • Patients with inability to perform neuropsychometric tests and to complete the SF-36 questionnaire as decided by the physician.

Trial contacts and locations

6

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems